The report is available in English with a Dutch summary - KCE

More documents

Recommendations

Info

38 Plasma KCE Reports 120 Key points • The production of plasma derivatives is not carried out only by the CAF- DCF, which has concluded agreements with foreign firms to carry out a part of the process • Relatively large volumes of plasma purchased by CAF-DCF do not contribute at all to the fractionation process. These volumes seem to vary greatly over the years, and this phenomenon has not been clarified. • The CAF-DCF seems to experience overcapacity for specific stable derivatives. In spite of the decrease of the volumes of purchased plasma, it produces more than it actually sells on the Belgian market. A proportion of collected plasma (under the form of intermediate product) is sometimes dedicated to the production for foreign markets. • Trading as well as production agreements, concluded between CAF-DCF partners, are not transparent towards the public authority, although this financially supports CAF-DCF through subsidized plasma prices. 2.2.3.4 Position of CAF-DCF on the international market The investments made by the CAF-DCF, notably in a new building in Neder-Over- Hembeek, enable the company to manufacture quality products that have resulted in foreign companies taking holdings in the capital of the CAF-DCF. Nevertheless, the CAF-DCF remains a very small enterprise on the world stage and its financial situation is precarious, despite the indirect subsidies it receives through the price that it pays for plasma to the Red Cross. An audit carried out in 2006 had already highlighted the difficult financial situation of the CAF-DCF. 9 According to this audit, the results of this enterprise in Belgium were in the red for the entire period under review (2000 – 2005) and the positive results of foreign operations were not enough to offset the losses made in Belgium. As from 2003, the purchases column saw a substantial increase due to the rise in the price of plasma from plasmapheresis (+37%). Two other cost headings were also to blame for the deterioration in the financial situation of the CAF-DCF during the period in question: ‘special orders’ and ‘purchases of stable derivatives’. The rise in the heading ‘special orders’ follows the closure of the former CAF fractionation factory in Ixelles. As from 2004, the plasma was fractionated into intermediate products in the factory at Neder-Over-Heembeek. The intermediate products are then sent to foreign partners for finer fractionation. Since 2002 the preparation of factor VIII has been carried out by the French company LFB. Since 2003 the albumin has been produced by Sanquin in the Netherlands. As for the rise in the heading ‘purchases of stable derivatives’, it results from a combination of two factors: the purchase of PPSB by Sanquin following the rise in demand for this product and the manufacture of Multigam (immunoglobulins) by the firm Biotest, which receives the intermediate products from the CAF-DCF and sends them back as the finished product. According to the audit conducted by F. Verhaegen, this negative financial situation should improve significantly with the removal of the compulsory levy on the pharmaceutical firms. Key points • The CAF-DCF is a high technology firm but rather small on the world-wide scale. • The financial situation of the CAF-DCF, structurally negative between 2000 and 2005, recovered thanks to the removal of the levy on pharmaceutical products, from which plasma derivatives are currently exempt
KCE Reports 120 Plasma 39 2.3 LIMITATIONS The subject we are dealing with is sensitive in more than one respect. Firstly, the products in question constitute, for a number of medical conditions, the only possible therapy at the present time. In addition, the data concerning the price and the quantities collected and produced concern actors that play an important role in this sector. It is therefore essential to have validated data in order to be able to draw relevant conclusions. It is also essential to identify the reasons why caution is necessary in the formulation of certain findings and conclusions, and we present here the limitations of our analysis. The first limitation concerns the cost of plasmapheresis. We have seen that the allocation of organisation costs to this activity, compared with the other activities of the Red Cross, could have a decisive effect on the real cost of the activity in question. The second limitation is related to the profitability of plasmapheresis. We are not in a position to establish with certainty the price at which the Red Cross could sell, or could have sold, plasma on the international market. The various data collected show that we cannot be sure of the profitability of such an approach because of the variability of prices in time and space.
Page 1 and 2: Hoe zelfvoorziening in stabiele pla
Page 3 and 4: Hoe zelfvoorziening in stabiele pla
Page 5 and 6: KCE Reports 120A Plasma i VOORWOORD
Page 7 and 8: KCE Reports 120A Plasma iii METHODO
Page 9 and 10: KCE Reports 120A Plasma v Elke lite
Page 11 and 12: KCE Reports 120A Plasma vii AANBEVE
Page 13 and 14: KCE Reports 120 Plasma 1 Scientific
Page 15 and 16: KCE Reports 120 Plasma 3 GLOSSARY A
Page 17 and 18: KCE Reports 120 Plasma 5 1 INTRODUC
Page 19 and 20: KCE Reports 120 Plasma 7 Focus: sta
Page 21 and 22: KCE Reports 120 Plasma 9 Two techni
Page 23 and 24: KCE Reports 120 Plasma 11 Therefore
Page 25 and 26: KCE Reports 120 Plasma 13 FRENCH-SP
Page 27 and 28: KCE Reports 120 Plasma 15 Number of
Page 29 and 30: KCE Reports 120 Plasma 17 Table 4:
Page 35 and 36: KCE Reports 120 Plasma 23 Role of t
Page 37 and 38: KCE Reports 120 Plasma 25 2.1.3.2 P
Page 39 and 40: KCE Reports 120 Plasma 27 • 73% o
Page 41 and 42: KCE Reports 120 Plasma 29 2.2 TRANS
Page 43 and 44: KCE Reports 120 Plasma 31 Figure 6:
Page 45 and 46: KCE Reports 120 Plasma 33 GEOGRAPHI
Page 47 and 48: KCE Reports 120 Plasma 35 It is sur
Page 49: KCE Reports 120 Plasma 37 Plasma fr
Page 55 and 56: KCE Reports 120 Plasma 43 3.2 INDIC
Page 57 and 58: KCE Reports 120 Plasma 45 Subcutane
Page 61 and 62: KCE Reports 120 Plasma 49 3.2.2 Evi
Page 63 and 64: KCE Reports 120 Plasma 51 Search re
Page 65 and 66: KCE Reports 120 Plasma 53 CIDP IG i
Page 67 and 68: KCE Reports 120 Plasma 55 • IG re
Page 69 and 70: KCE Reports 120 Plasma 57 Solid org
Page 71 and 72: KCE Reports 120 Plasma 59 A Cochran
Page 73 and 74: KCE Reports 120 Plasma 61 • In ch
Page 75 and 76: KCE Reports 120 Plasma 63 Two small
Page 77 and 78: KCE Reports 120 Plasma 65 was lower
Page 79 and 80: KCE Reports 120 Plasma 67 Three RCT
Page 81 and 82: KCE Reports 120 Plasma 69 Severe se
Page 83 and 84: KCE Reports 120 Plasma 71 The analy
Page 85 and 86: KCE Reports 120 Plasma 73 3.3.1.2 T
Page 87 and 88: KCE Reports 120 Plasma 75 Figure 7:
Page 89 and 90: KCE Reports 120 Plasma 77 Figure 10
Page 95 and 96: KCE Reports 120 Plasma 83 • For b
Page 97 and 98: KCE Reports 120 Plasma 85 3.3.2.6 L
Page 99 and 100: KCE Reports 120 Plasma 87 • The p
Page 101 and 102:
KCE Reports 120 Plasma 89 In Belgiu
Page 103 and 104:
KCE Reports 120 Plasma 91 Multifoca
Page 105 and 106:
KCE Reports 120 Plasma 93 Based on
Page 107 and 108:
KCE Reports 120 Plasma 95 Disease /
Page 109 and 110:
KCE Reports 120 Plasma 97 3.3.4 Exp
Page 111 and 112:
KCE Reports 120 Plasma 99 Figure 12
Page 113 and 114:
KCE Reports 120 Plasma 101 Key poin
Page 115 and 116:
KCE Reports 120 Plasma 103 Key poin
Page 117 and 118:
KCE Reports 120 Plasma 105 • Conf
Page 119 and 120:
KCE Reports 120 Plasma 107 As far a
Page 121 and 122:
KCE Reports 120 Plasma 109 Followin
Page 123 and 124:
KCE Reports 120 Plasma 111 4.3 HOW
Page 125 and 126:
KCE Reports 120 Plasma 113 Improvin
Page 127 and 128:
KCE Reports 120 Plasma 115 4.3.2 St
Page 129 and 130:
KCE Reports 120 Plasma 117 4.4 CONC
Page 131 and 132:
KCE Reports 120 Plasma 119 FAVOURIN
Page 133 and 134:
KCE Reports 120 Plasma 121 APPENDIX
Page 135 and 136:
KCE Reports 120 Plasma 123 For othe
Page 137 and 138:
KCE Reports 120 Plasma 125 Table 48
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
KCE Reports 120 Plasma 131 Distribu
Page 145 and 146:
KCE Reports 120 Plasma 133 • Conv
Page 147 and 148:
Page 149 and 150:
KCE Reports 120 Plasma 137 6 REFERE
Page 151 and 152:
KCE Reports 120 Plasma 139 41. Pruz
Page 153 and 154:
KCE Reports 120 Plasma 141 82. Comi
Page 155 and 156:
KCE Reports 120 Plasma 143 123. Cre
Page 157 and 158:
KCE Reports 120 Plasma 145 165. Cua
Page 159 and 160:
This page is left intentionally bla
Page 161 and 162:
KCE reports 1. Effectiviteit en kos
Page 163 and 164:
73. Financiering van het zorgprogra
show all

The report is available in English with a Dutch summary - KCE

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?